Scipio Bioscience raised EUR 6 million from an international syndicate led by M Ventures, the corporate venture capital arm of Merck. The initial shareholders Seventure Partners and High-Tech Gründerfonds participated in the capital increase, alongside additional investors Financière Arbevel and investiere. investiere contributed EUR 0.5 million in this round.

Scipio bioscience develops a new generation of single-cell sequencing solutions, to answer the growing needs of clinical and basic research labs. The patented technology is based on an innovative chemical approach conceived by its President and Co-Founder, Prof. Stuart Edelstein, a world-renowned biophysicist.

“Single-cell sample preparation is a major bottleneck in the sequencing workflow and represents a rapidly growing multi-billion market opportunity”, says Michael Lütolf, Investment Manager for investiere.

The company is headquartered in the iPEPS-ICM incubator of the Brain & Spine Institute in Paris.

The funding will fuel the final development of its single-cell RNA-sequencing kit, as well as marketing and business development efforts to prepare for commercial launch in 2022.